Wen Long, Hyoju Riza, Wang Peiru, Shi Lei, Li Chunxiao, Li Meng, Wang Xiuli
Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, P.R. China.
Lasers Surg Med. 2021 Mar;53(3):390-399. doi: 10.1002/lsm.23292. Epub 2020 Jun 28.
Recently, there has been a rapid increase in the incidences of melanoma, which represents a serious threat to human health. Generally, tumor-microenvironment-responsive nanoparticle-based photothermal-photodynamic combination therapy (PTT-PDT) is characterized by intratumoral response and tumor targeting. In this study, we designed and synthesized hydrogen-peroxide-responsive protein biomimetic nanoparticles (MnO -ICG@BSA) for the treatment of melanoma.
STUDY DESIGN/MATERIALS AND METHODS: Briefly, MnO -ICG@BSA was prepared using a mild protein synthesis method by loading indocyanine green (ICG) into a bovine serum albumin-manganese dioxide complex (MnO @BSA); next, its characteristics were determined. In addition, in vitro biocompatibility and antitumor efficacy were assessed using the classic cell counting kit-8 assay. Moreover, in vivo high-frequency ultrasound and thermal imaging were used to evaluate the oxygen-production capacity and photothermal conversion effect of MnO -ICG@BSA at the tumor site, and Singlet Oxygen Sensor Green (SOSG) was used to measure singlet oxygen levels in the tumor. The antitumor efficacy was assessed based on relative tumor size, bodyweight, survival curves, and hematoxylin and eosin staining.
The results showed that MnO -ICG@BSA has a high photothermal conversion efficiency, a strong singlet oxygen-generation ability, and high photothermal stability. In addition, in vitro PTT-PDT experiments showed that MnO -ICG@BSA has a significant inhibitory effect on the proliferation of B16F10 melanoma cells. Meanwhile, in vivo experiments showed that MnO -ICG@BSA has a significant inhibitory effect on melanoma in mice. Preliminary toxicity studies indicated that MnO -ICG@BSA exhibits low toxicity.
From the results, we can conclude that MnO -ICG@BSA could be used in PTT-PDT to treat melanoma, making it a good candidate material for PTT-PDT. Lasers Surg. Med. © 2020 Wiley Periodicals LLC.
近年来，黑色素瘤的发病率迅速上升，对人类健康构成严重威胁。一般来说，基于肿瘤微环境响应的纳米颗粒光热 - 光动力联合疗法（PTT - PDT）具有肿瘤内响应和肿瘤靶向的特点。在本研究中，我们设计并合成了用于治疗黑色素瘤的过氧化氢响应性蛋白质仿生纳米颗粒（MnO₂ - ICG@BSA）。
研究设计/材料与方法：简而言之，通过将吲哚菁绿（ICG）负载到牛血清白蛋白 - 二氧化锰复合物（MnO₂@BSA）中，采用温和的蛋白质合成方法制备MnO₂ - ICG@BSA；接下来，测定其特性。此外，使用经典的细胞计数试剂盒 - 8 法评估体外生物相容性和抗肿瘤疗效。此外，在体内利用高频超声和热成像评估MnO₂ - ICG@BSA在肿瘤部位的产氧能力和光热转换效果，并使用单线态氧传感器绿（SOSG）测量肿瘤中的单线态氧水平。基于相对肿瘤大小、体重、生存曲线以及苏木精和伊红染色评估抗肿瘤疗效。
结果表明，MnO₂ - ICG@BSA具有高光热转换效率、强单线态氧生成能力和高光热稳定性。此外，体外PTT - PDT实验表明，MnO₂ - ICG@BSA对B16F10黑色素瘤细胞的增殖具有显著抑制作用。同时，体内实验表明，MnO₂ - ICG@BSA对小鼠黑色素瘤具有显著抑制作用。初步毒性研究表明，MnO₂ - ICG@BSA表现出低毒性。
从结果可以得出结论，MnO₂ - ICG@BSA可用于PTT - PDT治疗黑色素瘤，使其成为PTT - PDT的良好候选材料。激光外科医学。©2020威利期刊有限责任公司。
